Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-09

Study Completion Date

2023-07-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, open-label, controlled clinical trial designed to compare clinical outcomes after kidney transplantation using extended-release tacrolimus (Envarsus XR) versus immediate tacrolimus among highly-sensitized kidney transplant recipients. Outcomes to be assessed include the incidence of biopsy-proven acute rejection at 12 months, the presence of de novo and pre-existing donor-specific HLA antibodies, estimated glomerular filtration rate, and the level of donor-derived cell-free DNA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant

NCT04665310

Kidney Disease, End-Stage Donor Specific Antibodies Acute Rejection of Renal Transplant

ACTIVE_NOT_RECRUITING PHASE4

Cognitive Outcomes in Stable Renal Transplant Patients Switched FromTacrolimus to Envarsus XR™

NCT04838288

Renal Transplant

ACTIVE_NOT_RECRUITING PHASE4

Envarsus XR Compared to Immediate Release Tacrolimus

NCT03979365

Kidney Transplant Recipients

COMPLETED PHASE4

Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation

NCT03511560

Renal Transplant Rejection Kidney Transplant Failure and Rejection

COMPLETED PHASE4

Expanded Access Study for Renal Transplant Patients With Envarsus XR ™

NCT02411604

Renal Failure

APPROVED_FOR_MARKETING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Extended-release tacrolimus (Envarsus XR) received FDA approval in July, 2015 for the prevention of allograft rejection in kidney transplantation on the basis of two separate phase 3 trials of de novo and stable kidney transplant recipients that demonstrated non-inferiority to immediate-release tacrolimus for the composite outcome of death, graft failure, biopsy-proven acute rejection, or loss to follow-up within 12 months (1,2).

Both phase 3 trials involved mostly low immunologic risk recipients with follow-up to one year. It has been previously shown that the incidence of de novo donor-specific antibodies (DSA) in the first year after kidney transplant in low-immunologic patients is low, developing in only 2%-11% of unsensitized de novo kidney transplant recipients (3-6). Donor-specific antibodies (DSA) are the primary mediator of antibody-mediated rejection and their development after transplant is a major risk factor for late allograft failure (7). It is now believed that antibody-mediated rejection is the most common cause of late allograft failure (8,9). However, neither of the two phase 3 trials were able to adequately assess the effect of Envarsus XR on the development of donor specific antibodies and therefore, the efficacy of Envarsus XR in higher immunologic risk recipients is not known. Therefore, a comparative study of extended- and immediate-release tacrolimus in highly-sensitized recipients is warranted.

This is a randomized, open-label, controlled clinical trial designed to compare clinical outcomes after kidney transplantation using extended-release tacrolimus (Envarsus XR) versus immediate tacrolimus among highly-sensitized kidney transplant recipients. Twenty patients will be enrolled, with ten assigned to each study arm. Outcomes to be assessed include the incidence of biopsy-proven acute rejection at 12 months, the presence of de novo and pre-existing donor-specific HLA antibodies, estimated glomerular filtration rate, and the level of donor-derived cell-free DNA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Transplant Rejection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Extended-release tacrolimus

Kidney transplant recipients will receive extended-release tacrolimus in addition to standard-dose mycophenolate and prednisone for maintenance immunosuppression.

Group Type EXPERIMENTAL

Extended-release tacrolimus

Intervention Type DRUG

Patients will receive the extended-release formulation of tacrolimus for maintenance immunosuppression.

Immediate-release tacrolimus

Kidney transplant recipients will receive immediate-release tacrolimus in addition to standard-dose mycophenolate and prednisone for maintenance immunosuppression.

Group Type ACTIVE_COMPARATOR

Immediate-release tacrolimus

Intervention Type DRUG

Patients will receive the immediate-release formulation of tacrolimus for maintenance immunosuppression.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Extended-release tacrolimus

Patients will receive the extended-release formulation of tacrolimus for maintenance immunosuppression.

Intervention Type DRUG

Immediate-release tacrolimus

Patients will receive the immediate-release formulation of tacrolimus for maintenance immunosuppression.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Recipient of a deceased or living donor kidney allograft
2. Patients must have undergone desensitization with Intravenous Immunoglobulin (IVIG) and rituximab with or without plasma exchange prior to transplant or be administered IVIG and rituximab peri-operatively (within seven days of transplant) post-transplant
3. Age 18 and over
4. Able to understand and provide informed consent
5. At transplant, patient must have an acceptable crossmatch \[as defined by a T- or B-flow crossmatch ≤ 225 median channel shift (MCS)\] from a non-HLA identical donor. A negative crossmatch is defined as a T pronase flow crossmatch \< 70 MCS or a T- flow crossmatch \< 50 MCS and a B pronase flow crossmatch \<130 MCS or a B-flow crossmatch \<100 MCS.

Exclusion Criteria

1. Recipients of a dual simultaneous kidney/liver, kidney/heart, kidney/lung, or kidney/pancreas transplant.
2. History of hypersensitivity to any of the study drug or to drugs of similar chemical classes.
3. Patients with a clinically significant systemic infection within 30 days prior to transplant.
4. Patients who have any history of a surgical or medical condition that may affect absorption of drug, such as severe diarrhea, active peptic ulcer disease, or uncontrolled diabetes mellitus, which in the opinion of the investigator at the time of enrollment, might significantly alter the absorption, distribution, metabolism and/or excretion of study medication.
5. Women of childbearing potential who are either pregnant, lactating, planning to become pregnant during this trial, or with a positive serum or urine pregnancy test. Women of childbearing potential must be willing to agree to contraceptive practices.
6. Patients who are Polymerase Chain Reaction (PCR) positive for hepatitis B, hepatitis C, or HIV.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No